Replimune's approval proves small biotechs can survive repeated FDA rejection and still win

The Food and Drug Administration cleared Replimune's skin cancer treatment on Thursday, the company's first product to reach market after two prior rejections tied to concerns about the quality of its clinical data.

For a small biotech, getting rejected twice and coming back is genuinely rare, as most companies in that position either run out of money or pivot, which makes this clearance a meaningful signal that the underlying science held up under scrutiny.

Amazon's $3 trillion milestone is really a story about cloud computing becoming the backbone of AI

Amazon crossed the $3 trillion market value mark after reporting record quarterly results, with its cloud division growing nearly 37% year over year and the company disclosing a nearly $500 billion backlog of future cloud contracts.

The decision to pour $220 billion into new infrastructure this year tells you everything about where Amazon's leadership thinks the next decade of growth is coming from: not retail, not advertising, but the raw computing power that AI runs on.

Chipotle's jalapeño problem is a reputational risk that earnings estimates alone can't capture

The CDC linked a multistate Salmonella outbreak to jalapeño peppers served at Chipotle and other Mexican-style restaurants, prompting the chain to pull the ingredient from some locations while federal investigators continue to look into whether the same peppers reached grocery store shelves.

Wall Street analysts are quick to say the financial hit will be modest, but food-safety scares have a way of living in consumers' heads long after the headlines fade, and Chipotle has been through this before.